Climent, MA, Font, A, Duran, I, Puente, J, Mendez-Vidal, MJ, Saez, MI, Lobera, CS, Arija, JAA, Gonzalez-Del-Alba, A, Sanchez-Hernandez, A, Fita, MJJ, Esteban, E, Alonso-Gordoa, T, Gonzalez, BM, Maroto, P, Lazaro-Quintela, M, Cassinello-Espinosa, J, Perez-Valderrama, B, Garcias, C, Castellano, D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. EUROPEAN JOURNAL OF CANCER. 2022; 175DOI:10.1016/j.ejca.2022.08.002. PMID:36099670. IF:8.400(Q1/2D).

Herbst, RS, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sanchez-Hernandez, A, Dakhil, S, Camidge, DR, Winzer, L, Soo-Hoo, Y, Cooper, ZA, Kumar, R, Bothos, J, Aggarwal, C, Martinez-Marti, A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(29)DOI:10.1200/JCO.22.00227. PMID:35452273. IF:45.300(Q1/1D).

Gonzalez-Barrallo, I, Rubio, VEC, Medina, J, Espana, S, Mujika, K, Majem, M, Aguado, C, Suarez, MAC, Palacio, I, Osterloh, L, Martinez-Fernandez, A, Garcia-Castano, A. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). MELANOMA RESEARCH. 2022; 32(5)DOI:10.1097/CMR.0000000000000837. PMID:35762583. IF:2.200(Q3/7D).

Alserawan, L, Anguera, G, Atenza, CZ, Lopez, JS, Martinez-Martinez, L, Melia, MR, Sullivan, I, Joaquin, AB, Tarruella, MM, Vidal, S. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(20)DOI:10.3390/ijms232012641. PMID:36293498. IF:5.600(Q1/3D).

Majem, M, Alvarez, R, Ortega, AL, de Alda, LR, Gordo, R, Garcia, JF, Ivanova-Markova, Y, Gonzalez-Dominguez, A, San Cristobal, RS, Rojo, F. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment. 2022; 9DOI:10.33393/grhta.2022.2449. PMID:36628311. IF:(Q/D).

Hwang, TJ, Kesselheim, AS, Tibau, A, Lee, CC, Vokinger, KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice. 2022; 18(9)DOI:10.1200/OP.21.00909. PMID:35731996. IF:4.000(Q2/4D).

Casarrubios, M, Provencio, M, Nadal, E, Insa, A, Garcia-Campelo, MD, Lazaro-Quintela, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Bernabe, R, Vinolas, N, Aranda, IB, Massuti, B, Sierra-Rodero, B, Martinez-Toledo, C, Fernandez-Miranda, I, Serna-Blanco, R, Romero, A, Calvo, V, Cruz-Bermudez, A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Journal for ImmunoTherapy of Cancer. 2022; 10(9)DOI:10.1136/jitc-2022-005320. PMID:36171009. IF:10.900(Q1/2D).

Hernandez, A, Munoz-Marmol, AM, Esteve-Codina, A, Alameda, F, Carrato, C, Pineda, E, Arpi-Llucia, O, Martinez-Garcia, M, Mallo, M, Gut, M, del Barco, S, Gallego, O, Dabad, M, Mesia, C, Bellosillo, B, Domenech, M, Vidal, N, Aldecoa, I, de la Iglesia, N, Balana, C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4.600(Q2/4D).